Profound Medical (TSE:PRN) has released an update.
Profound Medical has secured FDA 510(k) clearance for its ‘Contouring Assistant,’ an AI-based module enhancing the TULSA-PRO system for prostate treatment. This innovative tool, validated by top experts through clinical studies, improves the accuracy and speed of treatment planning by urologists. It represents a significant advancement in customizable, incision-free therapies for prostate disease, promising faster recovery and improved clinical outcomes.
For further insights into TSE:PRN stock, check out TipRanks’ Stock Analysis page.
